All In Biotech

Drug Trial Radar · NCT04223778

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

672

Actual

Start

Feb 18, 2020

Primary completion

Sep 8, 2021

Study completion Aug 26, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a protocol-specified antiretroviral regimen. The primary hypothesis is that a switch to MK-8591A will be non-inferior to continued treatment with baseline antiretroviral therapy (ART) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48.

Conditions

  • HIV Infection

Interventions

  • DOR/ISLDrug

    A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily

  • ARTDrug

    Baseline ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48Time frame: Week 48
  2. Percentage of Participants With One or More Adverse Events (AEs) up to Week 48Time frame: Up to ~48 Weeks
  3. Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48Time frame: Up to ~48 Weeks

Locations

78 sites in 15 countries. Site status is shown where the registry gives one.

  • Georgetown University Hospital ( Site 1018)

    Washington D.C., District of Columbia

  • Midway Immunology and Research ( Site 1030)

    Ft. Pierce, Florida

  • Orlando Immunology Center ( Site 1007)

    Orlando, Florida

  • Bliss Healthcare Services ( Site 1025)

    Orlando, Florida

  • Triple O Research Institute, P.A. ( Site 1026)

    West Palm Beach, Florida

  • Chatham County Health Department ( Site 1043)

    Savannah, Georgia

  • Northstar Healthcare ( Site 1002)

    Chicago, Illinois

  • Kansas City CARE Health Center ( Site 1008)

    Kansas City, Missouri

  • ID Care ( Site 1023)

    Hillsborough, New Jersey

  • University of North Carolina at Chapel Hill ( Site 1042)

    Chapel Hill, North Carolina

  • University of Pennsylvania ( Site 1038)

    Philadelphia, Pennsylvania

  • Saint Hope Foundation, Inc. ( Site 1037)

    Bellaire, Texas

  • North Texas ID Consultants, PA ( Site 1003)

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates P.A. ( Site 1022)

    Fort Worth, Texas

  • The Crofoot Research Center, Inc. ( Site 1005)

    Houston, Texas

  • Holdsworth House Medical Practice ( Site 2300)

    Sydney, New South Wales, Australia

  • Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 2309)

    Herston, Queensland, Australia

  • Melbourne Sexual Health Centre ( Site 2305)

    Carlton, Victoria, Australia

  • Fiona Stanley Hospital ( Site 2301)

    Murdoch, Western Australia, Australia

  • Southern Alberta HIV Clinic ( Site 1108)

    Calgary, Alberta, Canada

  • Vancouver ID Research and Care Centre Society ( Site 1100)

    Vancouver, British Columbia, Canada

  • Hamilton Health Sciences ( Site 1103)

    Hamilton, Ontario, Canada

  • Maple Leaf Research ( Site 1112)

    Toronto, Ontario, Canada

  • Toronto General Hospital - University Health Network ( Site 1105)

    Toronto, Ontario, Canada

  • Clinique de Medecine Urbaine du Quartier Latin ( Site 1104)

    Montreal, Quebec, Canada

  • Clinique Medicale L Actuel ( Site 1114)

    Montreal, Quebec, Canada

  • Hospital Dr. Hernan Henriquez Aravena ( Site 1305)

    Temuco, Araucania, Chile

  • Clinica Arauco Salud ( Site 1300)

    Santiago, Santiago Metropolitan, Chile

  • Centro de Investigacion Clinica UC CICUC ( Site 1303)

    Santiago, Santiago Metropolitan, Chile

  • Fundacion Valle del Lili ( Site 1201)

    Cali, Valle del Cauca Department, Colombia

  • A.P.H. Paris, Hopital Saint Louis ( Site 2014)

    Paris, France

  • Hopital de la Croix-Rousse ( Site 2027)

    Lyon, Auvergne-Rhône-Alpes, France

  • Hopital Francois Mitterrand ( Site 2019)

    Dijon, Cote-d'Or, France

  • CHU de Bordeaux- Hopital Saint Andre ( Site 2015)

    Bordeaux, Gironde, France

  • CHU de Toulouse - Hopital Purpan ( Site 2004)

    Toulouse, Haute-Garonne, France

  • CHU Hotel Dieu Nantes ( Site 2020)

    Nantes, Loire-Atlantique, France

  • CHU de Rouen ( Site 2005)

    Rouen, Seine-Maritime, France

  • ASST Fatebenefratelli-Ospedale Sacco ( Site 2200)

    Milan, Italy

  • A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 2208)

    Naples, Italy

  • Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 2206)

    Roma, Italy

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.